John Sweetenham, MD, PhD

Editorials by John Sweetenham, MD

Editorial

Saying goodbye

HemOnc Today, March 10, 2019
John Sweetenham, MD
I will shortly be leaving Utah to take up a new position at Harold C. Simmons Comprehensive Cancer Center at UT Southwestern in Dallas. Anyone who…
Editorial

Second opinions in oncology: Reducing frustration

HemOnc Today, February 10, 2019
John Sweetenham, MD
At a regular cancer service-line meeting last week, we reviewed our experience with pathology over-reads. Like many other centers, we at Huntsman…
Editorial

Choosing quality cancer care: The effect of branding

HemOnc Today, January 10, 2019
John Sweetenham, MD
“A brand is a reason to choose.” – Cheryl Burgess
Editorial

Getting the word out: Effective communication key to ensuring informed choices

HemOnc Today, December 10, 2018
John Sweetenham, MD
Among the many morning emails recently, one headline caught my attention. It reported the results of an ASCO survey that suggested about 40% of…
Editorial

Conflict management and data integrity in the shadows

HemOnc Today, November 10, 2018
John Sweetenham, MD
Consistent with the spirit of the Physician Payments Sunshine Act, the issue of financial conflicts of interest in the oncology domain has been…
Editorial

‘Insuring’ better outcomes

HemOnc Today, October 10, 2018
John Sweetenham, MD
In the last couple months, I have seen two young patients in my lymphoma clinic for whom insurance issues have had a significant effect on their…
Editorial

Cost-effectiveness and common sense

HemOnc Today, September 10, 2018
John Sweetenham, MD
Big-picture trends from ASCO’s most recent clinical practice survey — published in July with 2017 data — reflect ongoing…
Editorial

Natural language processing and the practice of hematology/oncology

HemOnc Today, August 10, 2018
John Sweetenham, MD
I will be in clinic the morning after I write this. Like most Tuesday mornings, I have a full schedule and need to stay close to being on time, given…
Editorial

Cancer clinical trials: Not suitable for prime time

HemOnc Today, July 10, 2018
John Sweetenham, MD
I am now very definitely within the demographic for those who watch prime-time TV. The best indicator of this is, of course, not the programming, but…
Editorial

Delivering on the promise of precision oncology

HemOnc Today, June 10, 2018
John Sweetenham, MD
The concept of genome-driven oncology became a reality almost 20 years ago with the introduction of imatinib, targeted to the ABL kinase. Even…